NCT00448383View on ClinicalTrials.gov

A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

6,610

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

November 30, 2004

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

adalimumab

40mg every other week

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY